IZONRO
LIVE

Serial Number

79352080

Owner

Sandoz AG

Filing Date

Jul 14, 2022

Add to watchlist:

No watchlists yet
View on USPTO

IZONRO Trademark

Serial Number: 79352080 • Registration: 7129122

IZONRO is a trademark filed by Sandoz AG on July 14, 2022. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

Sandoz AG (9 trademarks)

Viaduktstrasse 3

Entity Type: 03

Novartis AG (17 trademarks)

CH-4002 Basel

Entity Type: 03

Trademark Details

Filing Date

July 14, 2022

Registration Date

August 8, 2023

Published for Opposition

May 23, 2023

Goods & Services

Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for use in ophthalmology; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthma

Filing History

NEW REPRESENTATIVE AT IB RECEIVED
Sep 3, 2026 NREP
CHANGE OF OWNER RECEIVED FROM IB
Jan 19, 2024 CHLD
FINAL DECISION TRANSACTION PROCESSED BY IB
Dec 11, 2023 FINV
FINAL DISPOSITION NOTICE SENT TO IB
Nov 13, 2023 FICS
FINAL DISPOSITION PROCESSED
Nov 13, 2023 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Nov 8, 2023 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Aug 8, 2023 NRCC
REGISTERED-PRINCIPAL REGISTER
Aug 8, 2023 R.PR
NOTIFICATION PROCESSED BY IB
May 24, 2023 GPNX
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 23, 2023 NPUB
PUBLISHED FOR OPPOSITION
May 23, 2023 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
May 3, 2023 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
May 3, 2023 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 3, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 18, 2023 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 17, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 17, 2023 CRFA
ASSIGNED TO LIE
Apr 17, 2023 ALIE
REFUSAL PROCESSED BY IB
Feb 7, 2023 RFNT
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 20, 2023 TROA
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jan 18, 2023 RFCS
REFUSAL PROCESSED BY MPU
Jan 18, 2023 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Nov 8, 2022 RFCR
NON-FINAL ACTION WRITTEN
Nov 7, 2022 CNRT
ASSIGNED TO EXAMINER
Nov 3, 2022 DOCK
APPLICATION FILING RECEIPT MAILED
Oct 25, 2022 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 21, 2022 NWOS
LIMITATION FROM ORIGINAL APPLICATION ENTERED
Oct 20, 2022 LIMI
SN ASSIGNED FOR SECT 66A APPL FROM IB
Oct 13, 2022 REPR